Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 877

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 877
---
ished for no consideration.

(c) At the Effective Time, by virtue of the Mergers, the Pre-2023 Company Warrants, will terminate
upon their terms if such Pre-2023 Company Warrants are not previously exercised. If the Pre-2023 Company Warrants are exercised prior to the Effective Time, as a holder
of Shares, the holder of such former Pre-2023 Company Warrants will be entitled to receive the Merger Consideration as set forth in .

A-4

(d) At the Effective Time, by virtue of the Mergers, the 2023 Company Warrants, will be
entitled to the benefits as set forth in the applicable Warrantholder Treatment Agreement.

Section 2.3 . Immediately prior to the Closing, the Company will pay fees to the Exchange Agent to manage the disbursement of any cash payments received by the Company in connection with any Permitted Asset
Disposition Agreements (any such payment right, a “”) from the Closing Date until three years after the Closing Date (the “”). If any cash payment is received as the result
of a Disposed Asset Payment Right by the Exchange Agent in connection with any Permitted Asset Disposition Agreement during the Initial Period, (a) the holders of Shares will be entitled to receive cash equal to such Disposed Asset Payment
Right and (b) the Initial Period will be automatically extended for an additional three (3) years (the “”); , that the Exchange Agent’s fees for managing the disbursement of any
additional cash payments received as the result of a Disposed Asset Payment Right the Company in connection with any Permitted Asset Disposition Agreements during the Extended Period shall be funded through the deduction of the Exchange Agent’s
fee from the initial payment amounts being disbursed to the holders of Shares pursuant to .

Section 2.4 .

(a) Not later than two (2) Business Days before the Closing Date, the Company shall deliver to Parent and the Stockholders
Representative, the Company’s estimates, along with reasonable supporting detail thereof, of the Closing Liabilities and Debt (the “”), Unpaid Company Transaction Expenses (the
“”), the Closing Net Working Capital Amount (the “”) (including a reasonably detailed description of each component thereof) and,
based upon such Estimated Net Working Capital Amount, the difference between the Estimated Net Working Capital Amount and the Targeted Net Working Capital Amount (such surplus, if applicable, the “” and such deficit, if applicable, the “”),